Skip to main content
Open Access Publications from the University of California

Targeting the DNA repair pathway in Ewing sarcoma.

  • Author(s): Stewart, Elizabeth
  • Goshorn, Ross
  • Bradley, Cori
  • Griffiths, Lyra M
  • Benavente, Claudia
  • Twarog, Nathaniel R
  • Miller, Gregory M
  • Caufield, William
  • Freeman, Burgess B
  • Bahrami, Armita
  • Pappo, Alberto
  • Wu, Jianrong
  • Loh, Amos
  • Karlström, Åsa
  • Calabrese, Chris
  • Gordon, Brittney
  • Tsurkan, Lyudmila
  • Hatfield, M Jason
  • Potter, Philip M
  • Snyder, Scott E
  • Thiagarajan, Suresh
  • Shirinifard, Abbas
  • Sablauer, Andras
  • Shelat, Anang A
  • Dyer, Michael A
  • et al.

Ewing sarcoma (EWS) is a tumor of the bone and soft tissue that primarily affects adolescents and young adults. With current therapies, 70% of patients with localized disease survive, but patients with metastatic or recurrent disease have a poor outcome. We found that EWS cell lines are defective in DNA break repair and are sensitive to PARP inhibitors (PARPis). PARPi-induced cytotoxicity in EWS cells was 10- to 1,000-fold higher after administration of the DNA-damaging agents irinotecan or temozolomide. We developed an orthotopic EWS mouse model and performed pharmacokinetic and pharmacodynamic studies using three different PARPis that are in clinical development for pediatric cancer. Irinotecan administered on a low-dose, protracted schedule previously optimized for pediatric patients was an effective DNA-damaging agent when combined with PARPis; it was also better tolerated than combinations with temozolomide. Combining PARPis with irinotecan and temozolomide gave complete and durable responses in more than 80% of the mice.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View